Compare SOLAI Limited (SLAI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs BIO-TECHNE Corp — how do they compare? SOLAI Limited trades at $3.72 (market cap $16.69M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 673.5× SOLAI Limited's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| SLAI | TECH | |
|---|---|---|
Market Cap | $16.69M | $11.24B |
Sector | Technology | Health |
52-Week High | $26.74 | $72.29 |
52-Week Low | $2.74 | $43.31 |
Enterprise Value | $16.33M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement. The company faces severe financial distress with negative gross and net income margins, substantial losses, and a recent delisting notice from the NYSE. Technical indicators show a bullish signal despite fundamental weakness, while the sole analyst coverage maintains a hold rating. Recent corporate actions include a reverse stock split and acquisition activity.
The outlook remains highly speculative with significant execution and regulatory risks. Investment opportunity exists only for risk-tolerant investors betting on the company's AI infrastructure pivot, but current financials and delisting proceedings present substantial downside potential.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
